Tokyo, Septembe 02, 2018: Eisai Co., Ltd. announced that its South Korea subsidiary Eisai Korea Inc. received approval for the…
In Combination with KEYTRUDA as Therapy for Previously Treated Patients with Advanced and/or Metastatic non-MSI-H/pMMR Endometrial Carcinoma Tokyo, August 05,…